← Back to Screener
Intercure Ltd. Ordinary Shares (INCR)
Price$0.77
Favorite Metrics
Price vs S&P 500 (26W)-66.82%
Price vs S&P 500 (4W)-15.68%
Market Capitalization$41.86M
All Metrics
Book Value / Share (Quarterly)$3.35
P/TBV (Annual)3.45x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.83%
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)-32.39%
Gross Margin (TTM)31.25%
Net Profit Margin (TTM)-10.08%
EPS (TTM)$-0.42
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.42
Revenue Growth (5Y)92.97%
EPS (Annual)$-0.50
ROI (Annual)5.92%
Gross Margin (Annual)14.90%
Net Profit Margin (5Y Avg)-17.88%
Cash / Share (Quarterly)$0.75
Revenue Growth QoQ (YoY)236.68%
ROA (Last FY)4.68%
Revenue Growth TTM (YoY)45.15%
EBITD / Share (TTM)$-0.09
ROE (5Y Avg)-14.19%
Operating Margin (TTM)-5.28%
Cash Flow / Share (Annual)$0.23
P/B Ratio0.27x
P/B Ratio (Quarterly)0.46x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.38x
Net Interest Coverage (TTM)-1.86x
ROA (TTM)-6.81%
EV / EBITDA (TTM)5.39x
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)1.62x
Quick Ratio (Quarterly)1.39x
3-Month Avg Trading Volume0.09M
52-Week Price Return-74.82%
EV / Free Cash Flow (Annual)6.63x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)0.52x
Asset Turnover (Annual)0.41x
52-Week High$605.00
Operating Margin (5Y Avg)-14.60%
EPS Excl Extra (Annual)$-0.50
CapEx CAGR (5Y)-29.72%
Tangible BV CAGR (5Y)58.48%
26-Week Price Return-58.08%
Quick Ratio (Annual)1.22x
13-Week Price Return-27.06%
Total Debt / Equity (Annual)0.51x
Current Ratio (Quarterly)1.85x
Enterprise Value$72.038
Revenue / Share Growth (5Y)68.52%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)54.81%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.43x
Pretax Margin (Annual)-36.56%
Cash / Share (Annual)$1.71
3-Month Return Std Dev33.69%
Gross Margin (5Y Avg)35.34%
Net Income / Employee (TTM)$-0
ROE (Last FY)8.94%
Net Interest Coverage (Annual)-0.73x
EPS Basic Excl Extra (Annual)$-0.50
P/FCF (TTM)3.16x
Receivables Turnover (TTM)3.36x
EV / Free Cash Flow (TTM)18.96x
Total Debt / Equity (Quarterly)0.42x
EPS Incl Extra (TTM)$-0.42
Receivables Turnover (Annual)4.20x
ROI (TTM)-8.46%
P/S Ratio (TTM)0.22x
Pretax Margin (5Y Avg)-18.58%
Revenue / Share (Annual)$1.75
Tangible BV / Share (Annual)$0.03
Price vs S&P 500 (52W)-73.60%
Year-to-Date Return-29.13%
5-Day Price Return-3.78%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-8.76%
Net Profit Margin (Annual)-28.38%
Month-to-Date Return-3.58%
Cash Flow / Share (TTM)$0.18
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-28.14%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-9.62%
LT Debt / Equity (Quarterly)0.18x
EPS Basic Excl Extra (TTM)$-0.42
P/TBV (Quarterly)1.18x
P/B Ratio (Annual)1.11x
Inventory Turnover (TTM)3.44x
Pretax Margin (TTM)-10.48%
Book Value / Share (Annual)$3.69
Price vs S&P 500 (13W)-29.92%
Beta0.53x
P/FCF (Annual)3.95x
Revenue / Share (TTM)$4.16
ROE (TTM)-11.63%
52-Week Low$225.30
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INCRIntercure Ltd. Ordinary Shares | 0.22x | 45.15% | 31.25% | — | $0.77 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Intercure Ltd cultivates and produces pharmaceutical-grade cannabis products in dried flower and oil forms for the medical market. The company operates through two business segments: direct cannabis production and biomedical portfolio investments, with the majority of revenue derived from its cannabis operations.